

Attorney Docket No. 5470-255



RECEIVED

OCT 19 2000

DAC

GP1659

PATENT

# 8/43  
10-21-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2800

In re: Xiong et al.

Serial No.: 09/541,462

Filed: March 31, 2000

For: *Isolated DNA Encoding Cullin Regulators ROC1 and ROC2, Isolated Proteins Encoded by the Same, and Methods Utilizing the Same*

Examiner: R. Prouty  
Group Art Unit: 1652

Date: October 12, 2000

BOX SEQUENCE  
Commissioner for Patents  
Washington, DC 20231


RESUBMITTAL OF SEQUENCE LISTING TO COMPLY WITH THE  
REQUIREMENTS OF 37 C.F.R. § 1.821

Sir:

Enclosed is a copy of the Notice to Comply with the Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated September 12, 2000. Applicants respectfully note that a Preliminary Amendment to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, a paper copy of the Sequence Listing, and a computer-readable copy of the Sequence Listing were filed in the U.S. Patent and Trademark Office (PTO) on September 11, 2000. Copies of the paper copy of the Sequence Listing, the Amendment and the postcard that accompanied these documents (as stamped and returned to the undersigned by the PTO, indicating receipt by the same) are enclosed.

Applicant does not believe that any additional fee is now due. However, any additional fee or credit may be charged to our Deposit Account No. 50-0220.


Respectfully submitted,

  
Sorajini Biswas  
Registration No. 39,111

CUSTOMER NUMBER 20792  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, North Carolina 27627  
Telephone (919) 854-1400  
Facsimile (919) 854-1401

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Sequence, Assistant Commissioner For Patents, Washington, DC 20231, on October 12, 2000.

  
Meredith Schuessler  
Date of Signature: October 12, 2000



09-15-00A09:49, RCV'D

SJB

## UNITED STATES DEPARTMENT OF COMMERCE

## Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

88/541,482 03/31/00 XIUNG

5470-255

020792 HM22/0912  
MYERS BIGEL SIBLEY & SABOVEC  
PO BOX 37429  
RALEIGH NC 27627

EXAMINER

PRIORITY

ART UNIT

PAPER NUMBER

1652


DATE RECEIVED

RECEIVED

09/12/00

OCT 19 2000

TECH CENTER 1600/2900




Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.



RECEIVED

OCT 19 2000

TECH CENTER 1600/2000

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application:

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Any inquiry concerning this communication should be directed to Examiner Rebecca Prouty, Art Unit 1652, whose telephone number is (703) 308-4000.

Any inquiry of a general nature or relating to the status of this application should be directed to the Customer Service Center whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Rebecca Prouty  
Primary Examiner  
Art Unit 1652



RECEIVED

OCT 19 2000

TECH CENTER 1600/2000 Application No.: 09/541,462

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

RECEIVED

OCT 19 2000

TECH CENTER 1600/2900



SJB/mjs

September 11 2000

Commissioner for Patents  
Washington, DC 20231

Sir: Kindly acknowledge receipt of the accompanying by placing your receiving date stamp hereon and mailing:

1. Response to Comply with Requirements for Sequence Disclosures
2. Paper copy of Sequence Listing
3. Computer diskette with sequence listing

In re: Xiong et al.; Serial No. 09/541,462; Filed March 31, 2000; For:  
*Isolated DNA Encoding Cullin Regulators ROC1 and ROC2, Isolated Protein Encoded by the Same, and Methods Utilizing the Same.*

Respectfully submitted,  
MYERS BIGEL SIBLEY & SAJOVEC  
Attorneys for Applicant